PhD, Public Health and Health Systems
My thesis topic investigates the cost-effectiveness of tyrosine kinase inhibitors for the first-line treatment of lung cancer in Ontario, Canada.
Tyrosine kinase inhibitors (TKIs) work to inhibit the cancer proliferation process at the molecular level. These therapies are proven through clinical trials to help lung cancer patients live longer, while effectively delaying tumor progression. While several TKIs have been approved for use in Canada, the superiority of one TKI against another is relatively unknown.
Using data provided by Institute for Clinical Evaluative Sciences (ICES), my research aims to investigate the survival and economic outcomes associated with TKIs in a real-world setting. The results of this study may assist policymakers to optimize resource allocation decisions in the area of lung cancer.
My time in the School of Public Health and Health Systems (SPHHS)
My experience in the SPHHS at the University of Waterloo has been excellent so far. In addition to the multidisciplinary courses and projects that one can be involved in, the tight-knit chemistry between staff, faculty, and students helps to foster a great learning environment. The diversity within our school paired with the vast amount of resources to support student success really set the University of Waterloo apart!